Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 6

Mechanisms of Action and How They Alter the Pharmacokinetics of Drugs

Günlük Besin Olarak Soya Fasulyesindeki İzoflavonlar: Etki Mekanizmaları ve İlaçların Farmakokinetiğini Değiştirmeleri

Pages
799–810
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, the consumption of soybean, soy isoflavones or soy products with drugs needs to be reconsidered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Soybeans [Glycine max (L.)] are a good source of isoflavones.
📊
Key Findings & Data:The mechanisms of pharmacokinetic interactions occurs through the inhibition/induction of drug metabolizing cytochrome P450 (CYP450) enzymes such as CYP3A4, CYP2A1, and CYP2C9 or through the inhibition of drug transporters such as P-glycoprotein and breast cancer resistance protein.
💡
Conclusion & Impact:Thus, the consumption of soybean, soy isoflavones or soy products with drugs needs to be reconsidered.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Soybeans [Glycine max (L.)] are a good source of isoflavones. The main isoflavone components of soybean are daidzein, genistein, and glycitein. World soybean production is very high. Because of its pharmacological activity, soy isoflavone intake over a long period of time may result in interactions with the drugs. This review summarizes soy isoflavone-drug interactions based on the pharmacokinetic parameters. Soy isoflavones have pharmacokinetic interactions with celecoxib, theophylline, paclitaxel, midazolam, imatinib, carbamazepine, valproic acid, repaglinide, omeprazole and danofloxacin. This is due to the changes in the area under the curve, maximum serum concentration, time that a drug is present at the maximum concentration in serum, clearance and half-life of the drugs when delivered together with soy isoflavones. The mechanisms of pharmacokinetic interactions occurs through the inhibition/induction of drug metabolizing cytochrome P450 (CYP450) enzymes such as CYP3A4, CYP2A1, and CYP2C9 or through the inhibition of drug transporters such as P-glycoprotein and breast cancer resistance protein. Thus, the consumption of soybean, soy isoflavones or soy products with drugs needs to be reconsidered.

Özet

Soya fasulyesi [Glycine max (L.)] iyi bir izoflavon kaynağıdır. Soya fasulyesinin ana izoflavon bileşenleri daidzein, genistein ve glisitindir. Dünyada soya üretimi çok yüksektir. Farmakolojik aktivitesi nedeniyle, uzun süre soya izoflavon alımı, ilaçlarla etkileşime neden olabilir. Bu derleme, farmakokinetik parametrelere dayalı olarak soya izoflavon-ilaç etkileşimlerini özetlemektedir. Soya izoflavonları, selekoksib, teofilin, paklitaksel, midazolam, imatinib, karbamazepin, valproik asit, repaglinid, omeprazol ve danofloksasin ile farmakokinetik etkileşimlere sahiptir. Bunun nedeni, soya izoflavonları ile birlikte verildiğinde ilaçların eğrinin altındaki alan, maksimum serum konsantrasyonu, ilacın maksimum serum konsantrasyonunda bulunduğu süre, klirens ve yarılanma ömründe yaptığı değişikliklerdir. Farmakokinetik etkileşimlerin mekanizmaları ilaç metabolize eden sitokrom P450 (CYP450) enzimlerinin (örneğin; CYP3A4, CYP2A1 ve CYP2C9) inhibisyonu/indüklenmesi veya P-glikoprotein ve meme kanseri direnç proteini gibi ilaç taşıyıcılarının inhibisyonu yoluyla gerçekleşir. Bu nedenle soya fasulyesi, soya izoflavonları veya soya ürünlerinin ilaçlarla tüketimi yeniden gözden geçirilmelidir.

🔖

Cite This Article

RUSDIANA, T., SOYATA, A., HASANAH, A. N. (2022). Mechanisms of Action and How They Alter the Pharmacokinetics of Drugs. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 6, 799–810. https://ajindex.com/articles/613619

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Terzic D, Popovic V, Tatic M. Soybean area, yield and production. Ecol Mov Novi Sad. 2018;135-143
  2. Zaheer K, Humayoun Akhtar M. An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health. Crit Rev Food Sci Nutr. 2015;57:1280-1293
  3. Cheng PF, Chen JJ, Zhou XY, Ren YF, Huang W, Zhou JJ, Xie P. Do soy isoflavones improve cognitive function in postmenopausal women? A meta-analysis. Menopause. 2015;22:198-206
  4. Larkin T, Price WE, Astheimer L. The key importance of soy isoflavone bioavailability to understanding health benefits. Crit Rev Food Sci Nutr. 2008;48:538-552
  5. Tsourounis C. Clinical effects of phytoestrogens. Clin Obstet Gynecol. 2001;44:836-842
  6. Teekachunhatean S, Hanprasertpong N, Teekachunhatean T. Factors affecting isoflavone content in soybean seeds grown in Thailand. Int J Agron. 2013;2013:1-11
  7. Ahsan M, Mallick AK. The effect of soy isoflavones on the menopause rating scale scoring in perimenopausal and postmenopausal women: A pilot study. J Clin Diagnostic Res. 2017;11:13-16
  8. Agostoni C, Bresson J, Tait S, Flynn A, Golly I, Korhinen H. Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause. EFSA J. 2012;10:2847
  9. Chi XX, Zhang T. Isoflavone intake inhibits the development of 7,12 dimethylbenz(a)anthracene(DMBA) induced mammary tumors in normal and ovariectomized rats. J Clin Biochem Nutr. 2013;54:31-38
  10. Mace TA, Ware MB, King SA, Loftus S, Farren MR, McMichael E, Scoville S, Geraghty C, Young G, Carson WE 3rd, Clinton SK, Lesinski GB. Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. Sci Rep. 2019;9:5068
  11. Zhang X, Gao YT, Yang G, Li H, Cai Q, Xiang YB, Ji BT, Franke AA, Zheng W, Shu XO. Urinary isoflavonoids and risk of coronary heart disease. Int J Epidemiol. 2012;41:1367-1375
  12. Yoon GA, Park S. Antioxidant action of soy isoflavones on oxidative stress and antioxidant enzyme activities in exercised rats. Nutr Res Pract. 2014;8:618-624
  13. Sahin I, Bilir B, Ali S, Sahin K, Kucuk O. Soy isoflavones in integrative oncology: increased efficacy and decreased toxicity of cancer therapy. Integr Cancer Ther. 2019:1-11
  14. Mizushina Y, Shiomi K, Kuriyama I, Takahashi Y, Yoshida H. Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cance